Merck to Buy Idenix for $3.9B for Hepatitis C Drugs

June 9 (Bloomberg) -- Merck & Co. agreed to buy Idenix Pharmaceuticals Inc. for about $3.85 billion to add experimental drugs to treat hepatitis C. Adam Johnson reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)
Apple Delays iPad
35:42 - March 4 -- Bloomberg's Tim Higgins discusses the production of Apple's 12.9 inch iPad being pushed back to September. He speaks with Cory Johnson on "Bloomberg West." (Source: Bloomberg)
  • Etsy Files for IPO
  • `The Other Hundred' Releases Second Photo-Book
  • Meet iKeg: The Gathering-Data Beer Machine